Cameron Turtle, Chief Executive Officer at Spyre Therapeutics, Inc. (SYRE), sold 90,000 shares at $23.13 ($2.1M) on 2025-11-03, disclosed to the SEC on 2025-11-05.
Scheduled sale ($2.1M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.13 | 28,155 | $651K | 31.0% |
| 2 | $23.13 | 28,155 | $651K | 31.0% |
| 3 | $23.66 | 16,845 | $399K | 19.0% |
| 4 | $23.66 | 16,845 | $399K | 19.0% |
| Total | $23.33 avg | 90,000 | $2.1M | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $1.4M | — | Filing → |
| SYRE | SELL | 2026-07-02 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $1.1M | — | Filing → |